Sujiang Zhang

机构：Shanghai Jiao Tong University, Ruijin Hospital, Tongren Hospital, Shanghai Cancer Institute, Shanghai Institute of Hematology · ORCID：0000-0002-8481-0697

发表论文 22 篇 · 总被引 130 次 · h-index 6

代表论文

• The landscape of NUP98 rearrangements clinical characteristics and treatment response from 1491 acute leukemia patients (2024 · Blood Cancer Journal · 被引 33)
• Single-Cell Diagnosis of Cancer Drug Resistance through the Differential Endocytosis of Nanoparticles between Drug-Resistant and Drug-Sensitive Cancer Cells (2023 · ACS Nano · 被引 27)
• Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa‐2b (2024 · British Journal of Haematology · 被引 17)
• Acute myeloid leukemia patients with NUP98::NSD1 showing initially poor treatment response can benefit from FLT3 inhibitors and venetoclax as well as HSCT (2022 · Annals of Hematology · 被引 13)
• Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study (2025 · The Lancet Haematology · 被引 9)
• PICALM::MLLT10 may indicate a new subgroup of acute leukemias with miscellaneous immunophenotype and poor initial treatment response but showing sensitivity to venetoclax (2024 · eJHaem · 被引 6)